title: A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells.
abstract: Knockout, knock-in and conditional mutant gene-targeted mice are routinely used for disease modeling in the drug discovery process, but the human response is often difficult to predict from these models. It is believed that patient-derived induced pluripotent stem cells (iPSCs) could replace millions of animals currently sacrificed in preclinical testing and provide a route to new safer pharmaceutical products. In this review, we discuss the use of IPSCs in the drug discovery process. We highlight how they can be used to assess the toxicity and clinical efficacy of drug candidates before the latter are moved into costly and lengthy preclinical and clinical trials.
authors.affiliation: Centre for Biotechnology and Biomedicine, Department of Cell Techniques and Applied Stem Cell Biology, Medical Faculty of University of Leipzig, Deutscher Platz 5, 04103 Leipzig, Germany. Electronic address: shibashish.giri@bbz.uni-leipzig.de.
authors.forename: Shibashish
authors.initials: S
authors.lastname: Giri
authors.affiliation: Centre for Biotechnology and Biomedicine, Department of Cell Techniques and Applied Stem Cell Biology, Medical Faculty of University of Leipzig, Deutscher Platz 5, 04103 Leipzig, Germany.
authors.forename: Augustinus
authors.initials: A
authors.lastname: Bader
mesh_terms: D000818:Animals; D003365:Costs and Cost Analysis; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D005006:Ethnicity; D006801:Humans; D057026:Induced Pluripotent Stem Cells; D004364:Pharmaceutical Preparations / Q000378:metabolism; D011110:Polymorphism, Genetic; D011358:Product Surveillance, Postmarketing
chemical_list: D004364:Pharmaceutical Preparations